February 2025, Vol 2, No 2

Officials with Eisai Co., Ltd., and Biogen Inc. have announced the FDA nod for the supplemental biologics license application (sBLA) for once-every-4-weeks lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing. Read More ›

Vanzacaftor/tezacaftor/deutivacaftor (Alyftrek, Vertex Pharmaceuticals), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been approved for the treatment of cystic fibrosis (CF) in people aged ≥6 years who have at least 1 F508del mutation or another mutation in a responsive CFTR gene. Read More ›

On December 18, 2024, officials with the FDA approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), the first allogeneic bone marrow–derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft-versus-host-disease (SR-aGVHD) in pediatric patients aged ≥2 months. Read More ›

Officials with the Department of Veterans Affairs (VA) last month announced several Trump administration political appointees. Read More ›

Officials with Veterans Affairs (VA) are launching an outreach texting campaign that is set to include text messages and emails sent directly to veterans, public service announcements, paid advertising, and events. Read More ›

Officials with the Department of Defense have announced the replacement of the Tricare Online Portal with MHS Genesis. Read More ›